Curium confirms it is to merge with Lantheus Holdings (LNTH) in deal valued at USD 8bln, or USD 114.50/shr

Curium confirms it is to merge with Lantheus Holdings (LNTH) in deal valued at USD 8bln, or USD 114.50/shr.

Confirmed combinations in the radiopharmaceutical and diagnostic imaging space follow a well-worn sequence: the target's shares converge toward the offer terms, the acquirer's stock trades on funding mix and synergy credibility, and attention shifts to the spread as a live read on completion risk. Deals of this size in a specialist healthcare niche have historically drawn antitrust review where portfolios overlap, and the tell on regulatory risk is the width of the arb spread relative to the expected closing timeline rather than the headline multiple. The composition of consideration matters for the tape: all-cash terms pin the target near the offer price, while stock or mixed structures tie the target's mark to the acquirer's share price and widen the tradeable range. Prior form in this sector is consolidation driven by larger players buying isotope supply chains, manufacturing capacity, and pipeline assets rather than pure cost synergies, so the strategic rationale tends to hold up better than in defensive megamergers. Worth watching next are the financing details, any shareholder or litigation friction given the per-share valuation, and the stated timeline to close, since that sets the annualised return embedded in the spread.